Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC.

Simple Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging cancers to diagnose and treat. Despite over 4,300 clinical trials for pancreatic cancer exploring various treatments, progress in developing effective options for PDAC remains slow. This review seeks to offer a detailed and insightful analysis of the current landscape of PDAC-related clinical trials, with the primary goal of identifying ways to expedite drug development and enhance patient outcomes in the battle against this aggressive disease. Despite many decades of research, pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to diagnose and treat effectively. Although there have been improvements in the 5-year overall survival rate, it is still very low at 12.5%. The limited efficacy of current therapies, even when PDAC is detected early, underscores the aggressive nature of the disease and the urgent need for more effective treatments. Clinical management of PDAC still relies heavily on a limited repertoire of therapeutic interventions, highlighting a significant gap between research efforts and available treatments. Over 4300 clinical trials have been or are currently investigating different treatment modalities and diagnostic strategies for PDAC, including targeted therapies, immunotherapies, and precision medicine approaches. These trials aim to develop more effective treatments and improve early detection methods through advanced imaging techniques and blood-based biomarkers. This review seeks to categorize and analyze PDAC-related clinical trials across various dimensions to understand why so few chemotherapeutic options are available to patients despite the numerous trials being conducted. This review aims to provide a comprehensive and nuanced understanding of the landscape of PDAC-related clinical trials, with the overarching goal of identifying opportunities to accelerate progress in drug development and improve patient outcomes in the fight against this devastating disease. [ABSTRACT FROM AUTHOR]